減重及代謝手術

Page 1

手術治療糖尿病的趨勢 體重管理中心 宋天洲主任


“Diabetes is a public health emergency in slow motion” Ban Ki-Moon, UN Secretary-General


Where do nations rank in the global obesity stakes?


OECD Predictions for Future Overweight Rates


Obesity main driver for type 2 diabetes 80

Age 40-49 years Age 50-59 years

70 60 50 40 30 20 10 0

< 23

23 -23. 9

24-24.9

25-26.9

27-28. 9

29 -30. 9

31 -32. 9

33-34.9

> 35

Chan JM et al Diabetes Cars 1994


Diabetes Prevalence Rates in Selected Natios:1970-1989 & 1990-2005

Yoon KH et al. lancet 2006, 368 168 1-16888


Mauritius: Increase in Diabetes Prevalence over 22 yrs

Standardised to 2008 population structure of Mauritius


Global Projections for the Diabetes Epidemic:2010-2030 (millions) Wold 2010=285 million 2030=438 million Increase 54%

2011- a staggering 366 million 2030-552 million Shaw J. Diab ess & Clin Practice. 2009 IDF Atias 2009 www.idf org.




Conclusions • Diabetes continues to rise exponentially in Asia globally • Ageing, lifestyle change urbanisation have been targetted as the main drivers but in Asian nations, the story may be very different • A greater focus on early life risk factors eg maternal nutrition may lead to more effective strategies to halt this global “perfect storm” of diabetes • By 2020, diabetes is set to bankrupt the economies of many Asian nations


Diabetes “Cure” or Not


A surgical ‘cure’ for Diabetes??

N=168,146 with T2DM,152 with IFG

ANNALS OF SURGERY Vol.222,No. 3,339~352


• Rubino’s idea boils down to one impolite word used to refer to the excrement of steers


ADA Expert Consensus Statement

Diabetes Care 32:2133(2009)


Definition of “cure”


Surgeons and Endocrinologists


“The surgeon perspective”

“My daddy is a doctor and he treats diabetes.” “My daddy is a surgeon and he cures it.”


‌..but things can change


• Fist time that ADA acknowledgers surgery among “diabetes therapies”


The IDF Position Statement on Bariatric Surgery in obese type 2 diabetes


IDF Taskforce Consensus Panel Conveners: * Professor George Albert * Professor John B. Dixon * Professor Francesco Rubino * Professor Paul Zimmet Attendees: * Professor Stephanie Amiel * Professor Louise A. Baur * Professor Nam H. Cho * Dr. Bruno Geloneze * Professor Jan Willem Greve

* Professor Linong J. * Dr. Muffazal Lakdawala * Professor Wei-Jei Lee * Professor Pierre Lefebvre * Dr. Carel Ie Rour * Professor Jean-Claude Mbarrya * Professor Gertrude Mingrone * Dr. Philip R. Schauer * Professor Luc Van Gaal * Dr. David Whinng * Professor Bruce M. Wolfe


Management Algorithm for Metabolic Control in Type 2 Diabetes Lifestyle modification Diet modification Weight control Physical activity Metformin Bariatric sugary BMI >25 legible BMI >40 prioritized

FAILURE sulphonylureas

Acarbose

Dpp-4 inhibitor

glitazone insulin Basel

Premixed

Gabee insulin


Management Algorithm for Metabolic Control in Type 2 Diabetes Lifestyle modification Diet modification Weight control Physical activity Metformin Bariatric sugary BMI >25 legible BMI >40 prioritized

sulphonylureas Acarbose Barriatric surgery BMI >30 ebbic & BMI >25 Pefionitaed “It HbA1c-7.5% daspite Optinpend conventional Therapy espscially d weight is ie operative comobidities are Potreaathing farger on coventonal therapy

Dpp-4 inhibitor glitazone In Asian, and some other ethnicities of increased risk, BMI action points may be lower, e.g. BMI 27.5 to 32.5

insulin Basel

Premtaed

Gabee insulin


Bariatric surgery for obese adolescents with type 2 diabetes *An Australian report recommends surgery be considered if adolescents have BMI > 40, or >35 with severe co-morbidities, are 15 years or over & can provide informed consent. *This IDF position statement advises that only 2 procedures. Roux en Y gastric bypass & laparoscopic gastric banding are currently conventional bariatric surgical procedures for adolescents.


The idf position statement on bariatric surgery in obese type2 diabetes


Surgeons and Endocrinolongists


Glycemic and Metabolic Outcomes with Bariatric/Metabolic Surgery: Overview


Bariatric Surgery


What is the Evidence for Surgery as a Treatment for T2DM? BMI ≥ 35 • Retropective Studies • Prospective, Matched Controlled Studies • Prospective, Randomized Controlled Studies • Meta-analysis Studies


Weight and Type 2 Diabetes after Bariatric Surgery Systematic Review and Meta-analysis • 1990-2006:19 Studies, 4,070 diabetic patients

The American Journal of Medicine(2009) 122,248-256


Prospective, Matched Controlled Studies


Lifestyle, Diabetes, and Cardiovascular Risk Factors 10 years after Bariatric Surgery “SOS STUDY”

Sjo¨stro¨m L, et al. N Engl J Med 2004. 351.2683-93


Lifestyle, Diabetes, and Cardiovascular Risk Factors 10 years after Bariatric Surgery “SOS STUDY”

Sjo¨stro¨m L, et al. N Engl J Med 2004. 351.2683-93


Lifestyle, Diabetes, and Cardiovascular Risk Factors 10 years after Bariatric Surgery “SOS STUDY”

Sjo¨stro¨m L, et al. N Engl J Med 2004. 351.2683-93


Prospective, Randomized Controlled Studies


RCT: LAGB vs Med Rx of DM • • • • • • •

T2DM (< 2 yrs, Ha1c 7.7% no insulin) 60 patient (30 med RX. 30 surg RX follwed for 2 years) BMI 30-40 Med RX+ lifestyle vs. LAGB + Med Rx + lifestyle Remission @ 2 yrs 13% vs 73% (p<0.001) Wt. loss (%lnitial BW) @ 2 yrs 1.7% vs 20.7% (p<0.001) No serious side effects in either group

Dixon et al. JAMA. Jan 23,2008


LSG v RYGB BMI <35 • RCT LSG vs. RYGB • N=60, BMI 25-35, Age 30-59, A1c>7.5% • Remission: LSG 47% vs. RYGB 93% P<0.05 Lee WJ et.al Arch Surg. March 2011


Is Diabetes only about sugar? *What about all 3 endpoints? *HTN *Hypertriglyceridemia *HbA1C


Effects of Bariatric Surgery on CV Disease: Systematic Review Systematic Review -All types of bariatric -Effects on CV risk factors -DM .HTN. Bp CV risk score -FRS Novel CVD biomaker -CRP - 52 studies included Heneghan HM . Eldar S. Brethauer.S schauer PR. Young J:Am J Cardiol 2011


Effects on CV risk factors: Objective evidence *Mean follow up of 34 months Changes in blood pressure and laboratory measurements of CVD risk factors Baselin

postoperatively

Systolic

139

124

Diastolic

87

77

Fasting blood glucose (mg/dL)

125.99

91.85

HbA1C(%)

7.45

5.98

Total cholesterol

205

169

LDL

118

94

Triglycerides

169

103

HDL

49

52

Blood pressure (mm Hg)

Diabeted Mellitus

Lipid profile (mg/dL)

Heneghan HM. Eldar S. Brethance S. Schauce PR. Young J Am J Cardiol 2011


Effect on CV Risk • Data from J studies • Mean follow-up 34 months

40% relative risk Reduction after Bariatric surgery

Heneghan HM. Eldar S. Brethance S. Schauce PR. Young J Am J Cardiol 2011


Effect on CV Biomarkers: CRP •Mean follow-up 34 months 5

CRP level

4 3 2 1 0

Preoperative CRP

Postoperative CRP*

Heneghan HM. Eldar S. Brethance S. Schauce PR. Young J Am J Cardiol 2011


What about effect of surgery on Longterm Clinical Outcomes?

Sjostrom: NEJM 2007; 357:741-52


Unadjusted Cumulative Mortality Swedish Obesity Study

Sjostrom: NEJM 2007:357:741-52


Effect on Long-term Mortality Compared to Non-Operated Controls Study

Procedure

F/U

Mortality Reduction

MacDonald.1997

RYGB

9 yrs

88%

Flum. 2004

RYGB

4.4 yrs

33%

Christou.2004

RYGB

5 yrs

89%

Sowemimo. 2007

RYGB

4.4 yrs

50%

O’brien.2006

LAGB

12 yrs

73%

Adams. 2007

RYGB

8.4 yrs

40%

Sjostrom 2007

VBG/other

14 yrs

31%

Perry, 2008(Medicare)

RYGB.VBG LAGB

2 yrs

48% age <65 34% age >65


SOS JAMA 2012



Will Early Surgical Intervention Reduce progression of Microvascular and macrovascular disease?


Change in Nephropathy

DIABETES CARE, VOLUME 34,MARCH 2011


BMI <35 ?


Studies of “Metabolic Surgery” BMI <35

Fried M, Ribaric G et al. (2010) Obes surg 20(6):776-790


GI SURGERY for TYPE 2 DIABETES in ASIAN PATIENTS with BMI <35

1nd ADSS,2010.07.15-16 Taiwan, Taoyuan

2nd ADSS,2011.07.07 Taiwan, Taoyuan


ASIAN DIABETES SURGERY STUDY Wei-Jei Lee MD&hD1 Kyung Yul Hur MD2 Muffatal Lakadawala MD5; Yi-Chin Lee PH.D.,1 1.Department of surgery, Mi-Sheng General Hospital. Taiwan. 2.Department of Surgery, Soonchunhyang University hospital, Seoul, korea 3.Department of Surgery, Saifee hospital , Mumbai, India 4.Department of Surgery Yotsuya Medical Cube. Tokyo, Japan 5.Department of surgery. Dance of wales Hospital, Hong Kong


ASIAN DIABETES SURGERY STUDY Inclusion Criteria • • • • •

1.Asian, Age >18 years. 2.T2DM,Hba1c>7% 3.BMI ≤ 34.9 kg/m2 4.Receive gastro-intestinal Metabolic Surgery . 5.Complete pre- operative clinical data and post operation annual follow-up data.


Gastrointestianal Metabolic Surgery for the Treatment of Diabetic Patients: A multi-institutional International Study Befere (n=200)

After (n=87)

P_value

BMI (kg/m2)

28.5±3.3

23.4±3.1

0.027*

Waist (cm)

103.4±7.1

91.9±7.3

0.002*

Weight loss(%)

19.4%

SBP (mmHg)

130.1±14.8

128.8±18.2

0.003*

Olucose (mg/dl)

188.0±10.3

115.3±41.4

0.041*

Total cholesterol (mg/di)

202.0±44.7

119.9±58.8

0.000*

Triglyceride (mg/dl)

233.6±265.8

119.9±58.8

0.016&

LDL (mg/dr)

119.3±37.8

105.4±33.2

0.000*

HbA1c %

9.3±8

6.3±1.5

0.002*

C-peptide (ng/ml)

20±8

1.9±1.0

0.048*

HOMA

9.5±1.5.7

2.3±2.7

0.021*

p=0.05, BMI. Body mass index. SBP systolic blood pressure. DBP disease blood pressure HDL-C high-density lipoprotein cholesterol Lee WJ et al. J Gastrointst Surg 2012:16:45-52


Gastrointestianal Metabolic Surgery for the Treatment of Diabetic Patients: A multi-institutional International Study

BMI body mass index *p<0.05,

Lee WJ et al. J Gastrointst Surg 2012:16:45-52


Effects of “Bariatric� Operations on Gut Hormones, Insulin Secretion, Insulin sensitivity


Cummings De overdulin J ,J Clin inveset 2007


Ghrelin • Peptide hormone produced primarily by stomach & proximal small intestine • Powerfully stimulates appetite and food intake in many species, including humans


ACTH & Cortisol Epinephrine GHRELIN

Glucagon? Adiponectin Insulin Action Insulin Secretion Food Intake

counter. regulatory

GH

GLUCOSE


Plasma Ghrelin Increases After Diet-Induced Weight Loss

Cummings. et al. NEJM 346:1623




Lower Intestinal Hormones





Roux-en-Y Gastric Bypass (RYGB) Ingested food bypasses the duodenal site of nutrient mediated GLP-1 stimulation


Does gastric bypass Increase GLP-1 And/or PYY levels?


Increase in Postprandial GLP-1 and PYY After RYGB

Meal

Meal

Korner J, et al ,JCEM 90:359 Korner J, et al ,SOARD 3:597


GLP-1 For Up To 3 Years After RYGB

Laferrere et al ,unpublished


Operation That Rapidly Reverse DM All Expedite Nutrient Delivery to the Ileum

Roux-en-Y Gastric Bypass

…and All

Biliopancreatic Diversion

GLP-1 Levels

Jejuon-ileal Bypass GPT @20yrs


Are elevated GLP-1 levels after RYGB associated with an increased incretin effect?


Effects on Glucose Homeostasis of Equivalent Weight Loss from RYGB vs. Diet Type2 diabetes patients Matched for BMI, age, degree of diabetes

RYGB Studied at 9.7 kg

Diet Studied at 9.2 kg


Incretin Effect on Insulin Secretion Remains Normal up to One year After RYGB

No change in incretin Effect from equal Dietary weight loss

Bose M & Laferrere B. J Diabetes 2:47 (2010)


Higher C-Peptide Response to Oral Glucose After RYGB vs. Equivalent Dietary weight loss


Prandial GLP-1 response Increases immediately after RYGB, along with insulin


GLP-1 Meal Responses by 3 Days After RYGB


C-Peptide Responses by 3 Days After RYGB


Glucose Tolerance by 3 Days After RYGB



Acute Improvement in β-Cell Functin 4 Weeks After RYGB vs. Gastric Restriction Gastric Restriction

RYGB

Kashyap SR….Schauer PR. IJO 34:465 (2010)


Intestinal Bypass Operations That Increase Postprandial GLP-1 and Insulin Responses • Gastric bypass – e.g. LaFerrere. LeRoux. Korner. Holst. Schauer Mingrone. Morinigo. Peterli, Cummings • Biliopancreatic …but Diversion not seen with gastric banding or Dietary Efrrannini weight loss – e.g. Briatore, Mingrone, • Duodenal-Jejunal Bypass – e.g. Ramos


Bariatric Metabolic Surgery “An overview of safety”


Mortality Rates –Common GIT Surgical Procedures Procedure

Discharge

Mean Age

Mortality Rate

Small bowel resection

51,569

59

8.1%

Gastrostomy- temporary and permanent

93,693

73

7.9%

Gastrectomy – Partial and total

19,605

63

7.0%

Gastrointestinal therapeutic OR procedures

94,202

52

4.5%

Colorectal resection

280,969

64

4.2%

Lower GI Therapeubc OR procedures

113,271

52

2.5%

Hemia Repak

101,256

58

0.9%

Cholecystectomy and common duct exploration

407,582

53

0.8%

Fundoplic anti rethc Surgery

86,400

NR

0.8%

Gastric Bypass obesity Surgery

9,258

NR

0.5%**

Lap adjustable Gastric Band –Obesity surgery

5,780

NR

0.5%*


Mortality Rates – Common GIT Surgical Procedures Procedure

Number of Patients

Perioperative Mortality Rate

Gastric Bypass (Open)

437

2.1%

Cholecystectomy and common duct exploration

407,582

0.8%

fundoplication

86,400

0.8%

Appendectomy (Open

3,025

0.3%

Gastric Bypass (Laparoscopic)

2,975

0.2%

Appendectomy (Laparoscopic)

14,174

0.1%

LAGB-obesity surgery

5,780

0.05%


America College of surgeons National Surgical Quality Improvement Program LRYGB =3,580 LAGB =1,176 * 2006 included 4,756 patients * LAGB experienced an equivalent 30-day mortality ( 0.09% vs. 0.14%, P=10) * Lower rate of major complications(1.0% vs. 3.3%; p <0.0001) * Any complication (2.6% vs. 6.7% ; p<0.0001) * Return visits to the OR( 0.94% vs. 3.6%; p<0.0001) * Shorter postoperative LOS (median 1 vs. 2 days; p <0.0001)


Risk factors for major complications *History of VTE, mobility limitations, coronary artery disease, age over 50, pulmonary disease, male gender, smoking history and procedure type *Reference LAGB: * Duodenal switch (OR 9.68. CI 6.05-15.49) * Laparoscopic gastric bypass (OR 3.58,CI 2.79-4.64) * Open gastric bypass (OR3.51, CI 2.38-5.22); * Sleeve gastrectomy (OR 2.46, CI 1.73-3.50) Finks, J. F. K L.. Kole. et al. (2011), Ann Surg 254(4):633-640 “Predichng risk for complications with bariatric surgery : results from the Michigan Bariatiric Surgery Collaborative “


Combine rather than stop therapy • LDL – cholesterol • Hypertension • Diabetes treatment and prevention • Obstructive sleep apnea

Stopping therapy can put your patients at risk


Predictor factors ?


ABCE Score- DIABETES SURGERY SCORE The relative importance of pre-operative predictor variables Variables and point Values Used for the Computation of the Age. Body-Mass index. C-peptide and Duration of Diabetes (ABCD) index. Variable

Points on ABCD Index 0

1

2

3

Age

≼40

<40

BMI (kg/m2)

<30

30-39

40-49

>50

C-peptide (mmol/L) 0.9-1.9

2-3.9

4-6

>6

Duration of DM (years)

5-10

2-4.9

<2

>10


ABCE Score- DIABETES SURGERY SCORE The relative importance of pre-operative predictor variables Variables and point Values Used for the Computation of the Age. Body-Mass index. C-peptide and Duration of Diabetes (ABCD) index. ABCD index Sore

Patient No

Remission No

Remission %

0

3

1

33%

1

9

3

33%

2

30

13

43%

3

24

11

46%

4

17

7

41%

5

14

8

57%

6

24

20

83%

7

23

20

87%

8

15

15

100%

9

13

13

100%

10

4

4

100%

Overall

176

115

65.3%


From the Bariatric and Metabolic InstituteCleveland Clinic The mean (±SD) age of the patients at baseline was 48±8 years, HbA1c(%) level was 9.3±1.5%, BMI was 36.0±3.5.



HbA1c(%)

-0.6%

-2.5% -2.5%


BMI

-1.6

-6.9

-9.2



RAND 36-Item Health Survey


Conclusions *Including body weight, use of glucoselowering medications, and quality of life, also showed favorable results at 3 years in the surgical groups, as compared with the group receiving medical therapy alone. *Obese patients with uncontrolled type 2 diabetes, 3 years of intensive medical therapy plus bariatric surgery resulted in glycemic control in significantly more patients than did medical therapy alone.


台灣代謝及減重外科醫學會 Taiwan Society for Metabolic and Bariatric Surgery (TSMBS)

26.4% 25.2%


*Patient Character Male/Female Age (mean) BMI (mean) Hospital days (mean) Mortality Major complication 30 days Readmission 30 days Re-operation

849/1455 36.2 38.4 5.4 -> 4.8 0.17%( 4/2304) 1.5% 1.17%(27/2304) 1% (23/2304)



* 台灣代謝及減重外科醫學會 Taiwan Society for Metabolic and Bariatric Surgery (TSMBS)


2010~2014 嘉義基督教醫院


2014~2015 高雄阮綜合醫院


Characteristics of the Bariatric Surgery Patients (2014~2015) Total No. Female sex — no. (%) Male sex — no. (%) Age — yr Body weight — kg BodyBody-mass index ( BMI )

150 98 (63 (63.3%) 52 (36.7%) 37.2 ± 10.9 106.5 ± 24.2

Value < 32 — no. (%) 32 ≤ BMI < 40— 40— no. (%) 40 ≤ BMI < 50— 50— no. (%) ≥ 50— 50— no. (%) Hospitalized — day Diabetes— Diabetes— no. (%) Hypertension— Hypertension— no. (%) Hyperuricemia Hyperuricemia— uricemia— no. (%) Hepatic Steatosis— Steatosis— no. (%)

39.1 ± 7.4 8 (5.3%) 75 (5 (50.0%) 59 (3 (39.4%) 8 (5.3%) 4.5 ± 1.5 48 (32.0%) 56 (37.3%) 23 (15.3%) 96 (64%)





Thanks a lot for your attentionďź Sung,Tienchou. Tel: 0933153320

2015.08.14


Turn static files into dynamic content formats.

Create a flipbook
Issuu converts static files into: digital portfolios, online yearbooks, online catalogs, digital photo albums and more. Sign up and create your flipbook.